Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
In recent years, it has become clear that the fate of lymphocyte interactions with antigen is determined not only by signals through antigen-specific receptors, but by interactions between pairs of accessory molecules. One such crucial pair of ligands is that between CD80/CD86, expressed by professional APCs and activated T and B cells, and CD28 (resting and activated T cells primarily) and CTLA4 (activated T cells). Signals in this system can amplify (CD28) or inhibit (CTLA4) T cell responses. The uses of soluble competitors for CD28 (CTLA4-Ig) and agonists for the inhibitory receptor CTLA4 (CD80-Ig) offer therapeutic possibilities to tailor autoimmune responses in nonpathogenic directions.
Lane
P
P
Basel Institute for Immunology, Switzerland.
D000069594:Abatacept; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism*; D000943:Antigens, Differentiation / Q000378:metabolism*; D001402:B-Lymphocytes / Q000276:immunology*; D018122:B7-1 Antigen / Q000378:metabolism*; D051940:B7-2 Antigen; D018106:CD28 Antigens / Q000378:metabolism*; D060908:CTLA-4 Antigen; D017635:Clonal Anergy; D002999:Clone Cells / Q000378:metabolism; D006801:Humans; D018796:Immunoconjugates; D008562:Membrane Glycoproteins / Q000378:metabolism*; D012995:Solubility; D013601:T-Lymphocytes / Q000276:immunology*
D015703:Antigens, CD; D000943:Antigens, Differentiation; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D018106:CD28 Antigens; C497964:CD86 protein, human; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018796:Immunoconjugates; D008562:Membrane Glycoproteins; D000069594:Abatacept